Urinary Retention Clinical Trial
Official title:
Evaluation of the Safety and Clinical Performance of the Connected Catheter - Wireless Urinary Prosthesis for Management of Chronic Urinary Retention
Verified date | February 2024 |
Source | Spinal Singularity |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this study is to evaluate the safety and effectiveness of the Connected Catheter in males with chronic Urinary Retention, both in a clinical setting and an extended period of home use. The Connected Catheter is a fully internal, urethral indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization. It is a sterile, extended-use device that resides fully internally to the male lower urinary tract for an intended use life of up to 7 days per catheter.
Status | Terminated |
Enrollment | 26 |
Est. completion date | February 1, 2024 |
Est. primary completion date | February 1, 2024 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 22 Years and older |
Eligibility | Inclusion Criteria: - 1. Males > 22 years old diagnosed with chronic Urinary Retention 2. Must be clinically suitable and capable of safely managing bladder using an intermittent voiding or indwelling catheter strategy: 1. Must have stable urinary management history as determined by the Principal Investigator OR 2. Must have urodynamic profile suitable for the Connected Catheter (including bladder capacity = 200mL without uninhibited bladder contractions) 3. Subject's lower urinary tract anatomy must fall within the ranges serviceable by the Connected Catheter device, as specified in the Investigational Device Instructions For Use. Exclusion Criteria: - 1. Active symptomatic urinary tract infection, as defined in this clinical investigation plan (CIP)/protocol (subjects may receive the device after their UTI has been treated) 2. Significant risk profile or recent history of urethral stricture (e.g., stricture within past 90 days) 3. Significant risk profile or recent history of clinically significant (uncontrolled) autonomic dysreflexia 4. Significant intermittent urinary incontinence (between catheterizations) 5. Uninhibited bladder contractions and/or Vesicoureteral reflux that is not reliably controlled with medication or alternate therapy (e.g., Botox injection) 1. Active symptomatic urinary tract infection, as defined in this clinical investigation plan (CIP)/protocol (subjects may receive the device after their UTI has been treated) 2. Significant risk profile or recent history of urethral stricture (e.g., stricture within past 90 days) 3. Significant risk profile or recent history of clinically significant (uncontrolled) autonomic dysreflexia 4. Significant intermittent urinary incontinence (between catheterizations) 5. Uninhibited bladder contractions and/or Vesicoureteral reflux that is not reliably controlled with medication or alternate therapy (e.g., Botox injection) 6. Pre-existing urinary pathologies and/or morphological abnormalities of the lower urinary tract or bladder (assessed during in-depth medical screening, including cystoscopy and urine analysis) 1. Urinary tract inflammation or neoplasm 2. Urinary fistula 3. Bladder diverticulum (outpouching) > 5cm in size 4. Chronic pyelonephritis (secondary to upper urinary tract infection(s) within past 6 months) 5. Impaired kidney function or renal failure 6. Active gross hematuria 7. Active urethritis 8. Bladder stones 7. Dependence on an electro-magnetic medical implant (e.g., cardiac pacemaker or implanted drug pump) or external device 8. Any unsuitable comorbidities as determined by the Principal Investigator or complications related to use of certain medications 9. Any physical or cognitive impairments that diminish the subject's ability to follow directions or otherwise safely use the Connected Catheter System 10. Catheter Assessment Tool screening yields unacceptable results 11. Vulnerable population such as inmates or developmentally delayed adults |
Country | Name | City | State |
---|---|---|---|
United States | Rancho Research Institute | Downey | California |
United States | West Coast Urology, 575 E. Hardy St., Suite 215 | Inglewood | California |
United States | Tri Valley Urology, 25495 Medical Center Dr., Suite 204 | Murrieta | California |
United States | UCSD | San Diego | California |
United States | Medstar National Rehabilitation Hospital | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Spinal Singularity |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Successful Bladder Emptying Using Connected Catheter | PVR Responder Rate, defined as either:
Less than or equal to 50mL OR Equal to or less than their baseline PVR when using SOC catheters The subject responder rate, R, is estimated as the proportion of subjects who are classified as responders. |
4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05538273 -
Optimal Management of Urinary Catheter in Gyn Onc
|
||
Recruiting |
NCT05065255 -
Study of the Criteria for Choosing Speedicath Catheters During the Initiation of Self-catheterization
|
||
Completed |
NCT04236596 -
Pudendal Nerve Mapping Towards Improved Neuromodulation for Urinary Retention
|
N/A | |
Completed |
NCT05526651 -
Improvement of Urinary Retention Symptoms With Electroacupuncture Therapy
|
N/A | |
Not yet recruiting |
NCT06070545 -
The Effect of Modified Supine Position on Urinary Elimination After Percutaneous Coronary Intervention
|
N/A | |
Recruiting |
NCT03314025 -
Prophylactic Tamsulosin in Prevention of Post-operative Urinary Retention in Men After Transanal Endoscopic Microsurgery
|
Phase 2 | |
Recruiting |
NCT05439902 -
Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women
|
N/A | |
Enrolling by invitation |
NCT05259800 -
Peppermint Oil for Urinary Retention
|
N/A | |
Recruiting |
NCT06417346 -
Comparison of Laparoscopic and Open Inguinal Hernia Repair in Elderly Patients
|
N/A | |
Completed |
NCT03296280 -
Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program
|
||
Completed |
NCT04715971 -
Urinary Retention on an Acute Geriatric Hospitalisation Unit.
|
||
Completed |
NCT03302936 -
Assessing Pyridium for Post-Sling Urinary Retention
|
Phase 4 | |
Completed |
NCT02886143 -
Effect of Active vs. Passive Voiding Trials on Time to Discharge, Urinary Tract Infection, and Urinary Retention
|
Phase 3 | |
Completed |
NCT02749188 -
Evaluation of Bladder Stimulation as a Noninvasive Technique of Urine Collection in Infant Who Have Not Acquired Walking
|
N/A | |
Completed |
NCT01284361 -
Comparison of Two Intermittent Urinary Catheters
|
N/A | |
Completed |
NCT01220362 -
Effects of Thoracic Epidural Analgesia and Surgery on Lower Urinary Tract Function: A Randomized, Controlled Study
|
N/A | |
Terminated |
NCT00804557 -
Efficacy And Safety Of The Uro-Ease® Urinary Catheter During Clean Intermittent Catheterization
|
N/A | |
Terminated |
NCT00563654 -
Randomized Trial Comparing Alfuzosin GITS 10 mg Daily With Placebo for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up
|
N/A | |
Terminated |
NCT00563485 -
Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up
|
N/A | |
Terminated |
NCT04682366 -
The Effect of Tamsulosin on Postoperative Urinary Retention
|
Phase 4 |